Vertex Pharmaceuticals Inc

VRTX

Company Profile

  • Business description

    Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

  • Contact

    50 Northern Avenue
    BostonMA02210
    USA

    T: +1 617 341-6100

    E: [email protected]

    https://www.vrtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6,100

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,765.0241.550.54%
DAX 4024,205.07131.400.55%
Dow JONES (US)44,273.79132.57-0.30%
FTSE 1008,847.7241.190.47%
HKSE24,148.07260.241.09%
NASDAQ20,387.3025.22-0.12%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,859.0294.070.74%
S&P 5006,221.378.61-0.14%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers